Loading…
Neuroscience biotech (post-Pfizer Nurtec sale) now developing drugs for ataxia, epilepsy, obesity and neuromuscular disease.
Neuroscience biotech (post-Pfizer Nurtec sale) now developing drugs for ataxia, epilepsy, obesity and neuromuscular disease.
Became a separate company in 2022 when Pfizer bought the old Biohaven for its migraine drug Nurtec, leaving this new company with the rest of the pipeline. It has no product revenue and is funded by raising money from investors.
Moat: none (IP / patents). Pre-commercial pipeline company after divesting its only approved drug (Nurtec) to Pfizer.
Headquarters: New Haven, Connecticut, US · Founded: 2013 · Employees: 274
Size Biohaven (BHVN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.19B, the 1733rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $14.48 on 6 Nov 2026.
Performance Over six months the shares gained 46.9%, against -13.4% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Short interest Short interest is 11.8% of the free float (15 Oct 2026).
Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$2.86M | -$4.14M | -$3.92M | -$3.37M | -$1.39M |
| EBITDA | -$522M | -$741M | -$881M | -$433M | -$567M |
| Net income | -$543M | -$739M | -$846M | -$408M | -$570M |
| Free cash flow | -$473M | -$610M | -$587M | -$335M | -$304M |
| Capital expenditure | $642,000 | $715,000 | $4.05M | $3.05M | $41.1M |
| Total debt | $300M | $285M | $36.6M | $30.9M | $68.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Biohaven BHVN | $2.19B | +47% | n/a | n/a | n/a | n/a |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
| Neurocrine Biosciences NBIX | $16.7B | +8% | +38% | 25% | 4.4× | -1.7% |
| Xenon Pharmaceuticals XENE | $3.79B | +4% | -100% | n/a | n/a | n/a |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BHVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.4% | -0.6% | 2nd highest of 21 |
| 6-month return | +46.9% | -13.4% | 2nd highest of 21 |
| Distance from 52-week high | -20.6% | -27.1% | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 8.9× | 3.7% | +15.7% |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 1.3× | 13.1% | +0.8% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 3.4× | 6.1% | +6.4% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | 30.2× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | 15.5× | 37.9% | +0.9% |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | 62.8× | n/a | n/a |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 2.5× | 2.4% | +15.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | 34.7× | n/a | n/a |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 2.4× | -3.8% | +8.0% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 56.6× | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 0.9× | -2.9% | +8.2% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 4.4× | 1.6% | +0.3% |
| InnoCare Pharma 9969.HK | Hong Kong | $2.31B | -13% | +146% | 35% | 3.4× | 0.8% | +341.1% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% | -5.8% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 1.8× | -9.1% | -1.5% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 7.7× | 24.4% | -2.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 3.6× | -0.2% | +2.9% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 3.2× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 2.2× | 11.9% | +5.0% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 1.6× | 1.2% | +14.1% |